Associated Papers
Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer.
Yang Z et al.
Npj Breast Cancer, 2023
37160904 (PubMed )
Supplement: 41523_2023_542_MOESM1_ESM.pdf
Human papillomavirus integration perspective in small cell cervical carcinoma.
Wang X et al.
Nature Communications, 2022
36216793 (PubMed )
Supplement: 41467_2022_33359_MOESM22_ESM.xlsx › Supplementary_Data_19
Select a paper to view details